Source link : https://www.newshealth.biz/health-news/a-setback-for-tnbc-monitoring-with-circulating-tumor-dna-in-zest-trial/
SAN ANTONIO — A first-in-kind trial of molecular residual disease (MRD)-guided therapy in breast cancer came to an early end because of low randomization, but insights can still be gained on the potential use for circulating tumor DNA (ctDNA) to predict disease recurrence. The objective of the ZEST trial was to evaluate the potential of […]
Author : News Health
Publish date : 2024-12-15 22:42:20
Copyright for syndicated content belongs to the linked Source.